Apollon Formularies (AQSE:APOL) PLC said it started treating its first cancer patients using cannabis-based therapies at the International Cancer and Chronic Pain Institute in Kingston, Jamaica.
With expertise in cannabinoid medicine, the team will be led by Dr Margaret Dingle Spence.
"This is a huge milestone for Apollon,” said Stephen Barnhill, Apollon chairman and chief executive.
"After many years of researching, developing, manufacturing and testing these proprietary Apollon medical cannabis formulations, we are so proud to announce that they are now available to cancer patients by physician prescription at the International Cancer and Chronic Pain Institute."
The company’s formulations were recently shown to be highly effective in killing cancer cells in a pre-clinical assessment by BIOENSIS in the US using state-of-the-art 3D cell culture testing.